Adding aromatase inhibitors (AIs) to adjuvant treatment of postmenopausal women with hormone-receptor-positive breast cancer significantly reduces cancer recurrence. A common side effect of AIs is noninflammatory joint pain and stiffness (arthralgia) similar to arthritis symptoms. An evidence-based walking program developed by the Arthritis Foundation - Walk With Ease (WWE) - reduces arthritis-related joint symptoms. We hypothesized that WWE may also reduce AI-associated arthralgia. However, the potential for different barriers and facilitators to physical activity for these 2 patient populations suggested a need to adapt WWE before testing it with breast cancer survivors. We conducted qualitative research with 46 breast cancer survivors to...
arthralgia is emerging as a major source of symptom bur-den among its users, with a 28 % relative in...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...
Adding aromatase inhibitors (AIs) to adjuvant treatment of postmenopausal women with hormone-recepto...
Adding aromatase inhibitors (AIs) to adjuvant treatment of postmenopausal women with hormone-recepto...
BACKGROUND: In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone re...
BACKGROUND: Survival for stage I to III, hormone receptor-positive, breast cancer has substantially ...
Background: Survival for stage I to III, hormone receptor-positive, breast cancer has substantially ...
Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor positive br...
The third generation aromatase inhibitors (AI) have become an established component of treatment for...
Background: Women taking AIs (Aromatase Inhibitors) as treatment for breast cancer commonly experien...
ContextWomen taking aromatase inhibitors as treatment for breast cancer commonly experience joint pa...
Aromatase inhibitors reduce breast cancer recurrence rates in postmenopausal women by about 30% comp...
Background: Aromatase inhibitors reduce breast cancer recurrence rates in postmenopausal women by ab...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...
arthralgia is emerging as a major source of symptom bur-den among its users, with a 28 % relative in...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...
Adding aromatase inhibitors (AIs) to adjuvant treatment of postmenopausal women with hormone-recepto...
Adding aromatase inhibitors (AIs) to adjuvant treatment of postmenopausal women with hormone-recepto...
BACKGROUND: In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone re...
BACKGROUND: Survival for stage I to III, hormone receptor-positive, breast cancer has substantially ...
Background: Survival for stage I to III, hormone receptor-positive, breast cancer has substantially ...
Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor positive br...
The third generation aromatase inhibitors (AI) have become an established component of treatment for...
Background: Women taking AIs (Aromatase Inhibitors) as treatment for breast cancer commonly experien...
ContextWomen taking aromatase inhibitors as treatment for breast cancer commonly experience joint pa...
Aromatase inhibitors reduce breast cancer recurrence rates in postmenopausal women by about 30% comp...
Background: Aromatase inhibitors reduce breast cancer recurrence rates in postmenopausal women by ab...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...
arthralgia is emerging as a major source of symptom bur-den among its users, with a 28 % relative in...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...
BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving a...